Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

198 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial.
Weathers SP, Penas-Prado M, Pei BL, Ling X, Kassab C, Banerjee P, Bdiwi M, Shaim H, Alsuliman A, Shanley M, de Groot JF, O'Brien BJ, Harrison R, Majd N, Kamiya-Matsuoka C, Fuller GN, Huse JT, Chi L, Rao G, Weinberg JS, Lang FF, Sawaya R, Shpall EJ, Rezvani K, Heimberger AB. Weathers SP, et al. Among authors: de groot jf. Clin Cancer Res. 2020 Jul 15;26(14):3565-3577. doi: 10.1158/1078-0432.CCR-20-0176. Epub 2020 Apr 16. Clin Cancer Res. 2020. PMID: 32299815 Free PMC article. Clinical Trial.
Neutrophils promote the malignant glioma phenotype through S100A4.
Liang J, Piao Y, Holmes L, Fuller GN, Henry V, Tiao N, de Groot JF. Liang J, et al. Among authors: de groot jf. Clin Cancer Res. 2014 Jan 1;20(1):187-98. doi: 10.1158/1078-0432.CCR-13-1279. Epub 2013 Nov 15. Clin Cancer Res. 2014. PMID: 24240114 Free PMC article.
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.
Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De Groot JF, Puduvalli VK, Colman H, Volas-Redd G, Giglio P, Conrad CA, Salacz ME, Floyd JD, Loghin ME, Hsu SH, Gonzalez J, Chang EL, Woo SY, Mahajan A, Aldape KD, Yung WK, Gilbert MR; MD Anderson Community Clinical Oncology Program; Brain Tumor Trials Collaborative. Penas-Prado M, et al. Among authors: de groot jf. Neuro Oncol. 2015 Feb;17(2):266-73. doi: 10.1093/neuonc/nou155. Epub 2014 Sep 19. Neuro Oncol. 2015. PMID: 25239666 Free PMC article. Clinical Trial.
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.
Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M. Butowski N, et al. Among authors: de groot jf. Neuro Oncol. 2016 Apr;18(4):557-64. doi: 10.1093/neuonc/nov245. Epub 2015 Oct 8. Neuro Oncol. 2016. PMID: 26449250 Free PMC article. Clinical Trial.
A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.
Weathers SP, Han X, Liu DD, Conrad CA, Gilbert MR, Loghin ME, O'Brien BJ, Penas-Prado M, Puduvalli VK, Tremont-Lukats I, Colen RR, Yung WKA, de Groot JF. Weathers SP, et al. Among authors: de groot jf. J Neurooncol. 2016 Sep;129(3):487-494. doi: 10.1007/s11060-016-2195-9. Epub 2016 Jul 12. J Neurooncol. 2016. PMID: 27406589 Free PMC article. Clinical Trial.
Prioritization schema for immunotherapy clinical trials in glioblastoma.
Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, Jiang T, Mikkelson T, Yung WK, de Groot JF, Fine H, Cantley LC, Mellinghoff IK, Mitchell DA, Okada H, Heimberger AB. Hodges TR, et al. Among authors: de groot jf. Oncoimmunology. 2016 Feb 18;5(6):e1145332. doi: 10.1080/2162402X.2016.1145332. eCollection 2016 Jun. Oncoimmunology. 2016. PMID: 27471611 Free PMC article. Review.
198 results